Publications

ADDITION-EUROPE

Sort by: Date | Author | Title

2015

2014

2013

2011

2008

2000

ADDITION-DK

Sort by: Date | Author | Title

2015

ADDITION-UK

2016

  • Patient-centred care, health behaviours and cardiovascular risk factor levels in people with recently diagnosed type 2 diabetes: 5 year follow-up of the ADDITION-plus trial cohort. Dambha-Miller H, Cooper AJM, Simmons RK, Kinmonth AL, Griffin SJ. BMJ Open 2016;6(1):e008931.
  • Prospective associations between sedentary time, physical activity, fitness and cardiometabolic risk factors in people with type 2 diabetes. Lamb MJE, Westgate K, Brage S, Ekelund U, Long GH, Griffin SJ, Simmons RK, Cooper AJM. Diabetologia 2016;59:110-120.

2015

  • Objectively measured sedentary time, physical activity and kidney function in people with recently diagnosed type 2 diabetes: a prospective cohort analysis. Guo VYW, Brage S, Ekelund U, Griffin SJ, Simmons RK. Diabetic Med 2015;doi: 10.1111/dme.12886.
  • Change in cardio-protective medication and health-related quality of life after diagnosis of screen-detected diabetes: results from the ADDITION-Cambridge cohort. Black JA, Long GH, Sharp SJ, Kuznetsov L, Boothby CE, Griffin SJ, Simmons RK. Diab Res Clin Pr 2015;109:170-177.
  • Long-term effect of population screening for diabetes on cardiovascular morbidity, self-rated health, and health behavior. Echouffo-Tcheugui JB, Simmons RK, Prevost AT, Williams KM, Kinmonth AL, Wareham NJ, Griffin SJ. Ann Fam Med 2015;13:149-157.
  • Which behavior change techniques are associated with changes in physical activity, diet and BMI in people with recently diagnosed diabetes? Hankonen N, Sutton S, Prevost TA, Simmons RK, Griffin SJ, Kinmonth AL, Hardeman W. Ann Behav Med 2015;49:7-17.
  • Sleep duration and cardiometabolic risk factors among individuals with type 2 diabetes. Cooper AJM, Westgate K, Brage S, Prevost AT, Griffin SJ, Simmons RK. Sleep Med 2015;16:119-125.
  • Are changes in glycaemic control associated with diabetes-specific quality of life and health status in screen-detected type 2 diabetes patients? Four-year follow up of the ADDITION-Cambridge cohort. Kuznetsov L, Long GH, Griffin SJ, Simmons RK. Diabetes Metab Res Rev 2015;31:69-75.

2014

  • Multiple behaviour change intervention and outcomes in recently diagnosed type 2 diabetes: the ADDITION-Plus randomised controlled trial. Griffin SJ, Simmons RK, Prevost AT, Williams KM, Hardeman W, Sutton S, Brage S, Ekelund U, Parker RA, Wareham NJ, Kinmonth AL. iabetologia 2014;57:1308–1319.
  • Healthy behaviour change and cardiovascular outcomes in newly diagnosed type 2 diabetes patients: A cohort analysis of the ADDITION-Cambridge study. Long GH, Cooper AJM, Wareham NJ, Griffin SJ, Simmons RK. Diabetes Care 2014;37:1712-1720.
  • Do improvements in dietary behaviour contribute to cardiovascular risk factor reduction over and above cardio-protective medication in newly diagnosed diabetes patients? Cooper AJM, Schliemann D, Long GH, Griffin SJ, Simmons RK. Eur J Clin Nutr 2014;68:1113-1118.
  • Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: A cross-sectional analysis of the ADDITION-Europe trial cohort. Kuznetsov L, Griffin SJ, Davies MJ, Lauritzen T, Khunti K, Rutten GEHM, Simmons RK. Diab Res Clin Pr 2014;104:281-287.
  • Changes in diet, cardiovascular risk factors and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort. Savory LA, Griffin SJ, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Simmons RK. Diabet Med 2014;31:148155.
  • Association between objectively assessed sedentary time and physical activity with metabolic risk factors among people with recently diagnosed type 2 diabetes. Cooper AJM, Brage S, Ekelund U, Wareham NJ, Griffin SJ, Simmons RK. Diabetologia 2014;57:73-82.

2013

  • Predictors of change in objectively measured and self-reported health behaviours among individuals with recently diagnosed type 2 diabetes: longitudinal results from the ADDITION-Plus trial cohort. Kuznetsov L, Simmons RK, Sutton S, Kinmonth AL, Griffin SJ, Hardeman W on behalf of the ADDITION-Plus study team. Int J Behav Nutr Phys Act 2013;10:118.
  • Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort. Tao L, Wilson E, Griffin SJ, Simmons RK. Value Health 2013;16:1074-1080.
  • Changes in physical activity and modelled cardiovascular risk following diagnosis of diabetes: one-year results from the ADDITION-Cambridge trial cohort. Barakat A, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ, Simmons RK. Diabetic Med 2013;30:233–238.
  • Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Lancet 2012;380:1741–48. BMJ research paper of the year 2013, Category Award for Diabetes in the RCGP Research Paper f the Year 2012 Award.

2012

  • Cardiovascular risk reduction following diagnosis of diabetes by screening: one-year results from the ADDITION-Cambridge trial cohort. Charles M, Simmons RK, Williams KM, Roglic G, Sharp SJ, Kinmonth AL, Wareham NJ, Griffin SJ. Brit J Gen Pract 2012;62:294-295.
  • Intensive multifactorial intervention improves modelled five year coronary heart disease risk in screen-detected type 2 diabetes mellitus: a cluster randomized controlled trial. Webb DR, Khunti K, Gray LJ, Srinivasan BT, Farooqi A, Wareham N, Griffin SC, Davies MJ for the ADDITION-Leicester study group. Diabetic Med 2012;29:531-540.

2011

  • Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Webb DR, Gray LJ, Khunti K, Srinivasan B, Taub N, Campbell S, Barnett J, Farooqi A, Echouffo-Tcheugui JB, Griffin SJ, Wareham NJ, Davies MJ. Diabetologia 2011;54:2237–2246.
  • Protocol for the ADDITION-Plus study: a randomised controlled trial of an individually-tailored behaviour change intervention among people with recently diagnosed type 2 diabetes under intensive UK general practice care. Griffin SJ, Simmons RK, Williams KM, Prevost AT, Hardeman W, Grant J, Whittle FC, Boase SA, Hobbis I, Brage S, Westgate K, Fanshawe T, Sutton SR, Wareham NJ, Kinmonth AL. BMC Public Health 2011;11:211.
  • Predictors of anxiety and depression among people attending diabetes screening: A prospective cohort study embedded in the ADDITION (Cambridge) Randomized Control Trial. Paddison CAM, Eborall HC, French DP, Kinmonth AL, Prevost AT, Griffin SJ, Sutton S. Brit J Health Psych 2011;16:213-26.

2010

  • Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Diabetic Med 2010;27:995–1003.
  • A randomised evaluation of loss and gain frames in an invitation to screening for type 2 diabetes – effects on attendance, anxiety and self-rated health. Park PJ, Simmons RK, Prevost AT, Griffin SJ. J Health Psych 2010;15:196-204.
  • Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Webb D, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S, Barnett J, Henson J, Hiles S, Farooqi A, Griffin SJ, Wareham NJ, Davies MJ. BMC Trials 2010;11:16.

2009

  • Are people with negative screening tests falsely reassured?  A parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. Paddison CAM, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT, Kinmonth AL, Griffin SJ. BMJ 2009;339:b4535.
  • The ADDITION-Cambridge trial protocol - a cluster randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients.  Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. BMC Public Health 2009;9:136.
  • Completing a postal health questionnaire did not affect anxiety or related measures: randomized controlled trial. French DP, Eborall H, Griffin S, Kinmonth AL, Prevost AT, Sutton S. J Clin Epidemiol 2009; 62:74-80.

2008

  • How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, Williams KM, Barling RS, Butler R, Fanshawe T, Kinmonth AL, Wareham NJ, Griffin SJ. Diabetic Med 2008;25:1433–1439.
  • Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. Park P, Simmons RK, Prevost AT, Griffin SJ. BMC Public Health 2008;8:350.

2007

  • Patients’ experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. Eborall HC, Davies R, Kinmonth AL, Griffin S, Lawton J. BMJ 2007;335:490-493.
  • Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. BMJ 2007;335:486-489.

2000

  • The effect of varying the screening interval on false positives and duration of undiagnosed disease in a screening programme for type 2 diabetes. Park PJ, Griffin SJ, Duffy SW, Wareham NJ. J Med Screen 2000;7:91-96.

 

 

ADDITION-NL

 

  • Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes. den Ouden H, Pellis L, Rutten GE, Geerars-van Vonderen IK, Rubingh CM, van Ommen B, van Erk MJ, Beulens JW. Metabolomics. 2016;12:27. Epub 2016 Jan 6.
  • Effect of six years intensified multifactorial treatment on levels of hs-CRP and adiponectin in patients with screen detected type 2 diabetes: the ADDITION-Netherlands randomized trial. den Ouden H, Berends J, Stellato RK, Beulens JW, Rutten GE. Diabetes Metab Res Rev. 2015 Oct;31(7):758-66. doi: 10.1002/dmrr.2669. Epub 2015 Jul 30.
  • Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes-the ADDITION-Netherlands study: a cluster-randomized trial. Koekkoek PS, Ruis C, van den Donk M, Biessels GJ, Gorter KJ, Kappelle LJ, Rutten GE. J Neurol Sci. 2012 Mar 15;314(1-2):71-7. doi: 10.1016/j.jns.2011.10.028. Epub 2011 Nov 16.
  • No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients. The ADDITION-Netherlands study. van den Donk M, Gorter KJ, Rutten GE. Qual Life Res. 2010 May;19(4):509-13. doi: 10.1007/s11136-010-9604-x. Epub 2010 Feb 13.
  • Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study.  Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Br J Gen Pract. 2009 Jan;59(558):43-8. doi: 10.3399/bjgp09X394851.
  • Three years follow-up of screen-detected diabetic and non-diabetic subjects: who is better off? The ADDITION Netherlands study. Janssen PG, Gorter KJ, Stolk RP, Akarsubasi M, Rutten GE. BMC Fam Pract. 2008 Dec 16;9:67. doi: 10.1186/1471-2296-9-67.
  • Do characteristics of practices and general practitioners influence the yield of diabetes screening in primary care? The ADDITION Netherlands study.  Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Scand J Prim Health Care. 2008;26(3):160-5. doi: 10.1080/08037050802117924.
  • Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study.  Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Fam Pract. 2007 Dec;24(6):555-61. Epub 2007 Oct 25.
  • Effectiveness of a self-management intervention in patients with screen-detected type 2 diabetes. Thoolen B, De Ridder D, Bensing J, Maas C, Griffin S, Gorter K,  Rutten G. Diabetes Care. 2007 Nov;30(11):2832-7. Epub 2007 Jul 31.
  • Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: the ADDITION Netherlands study. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Prim Care Diabetes. 2007 Jun;1(2):69-74. doi: 10.1016/j.pcd.2007.02.001. Epub 2007 Mar 29.